Executives from the top orthopedic companies discuss procedure volumes, VBP impact and the footprint of robotics.
The Numbers
Stay up to date on the orthopedic market’s 3Q performance in 2024 as we update this post with company sales data and industry developments.
The company grew 63% on a reported basis in the third quarter of 2024 as it anniversaried its merger with NuVasive.
Orthoflash®
Icona is designed to ease implantation in muscle-sparing approaches, such as the Direct Anterior Approach.
December 11, 2024
,
The multicenter one- and two-level trial is designed to support a future Premarket Approval application for MOVE-C.
December 11, 2024
,
Designed with or without integrated fixation and options to gain up to 30 degrees of angulation, the implant can be adjusted intra-operatively, to fit each patient’s needs.
December 10, 2024
,
FDA approved an expansion to its Phase I/II clinical program to include three spinal fusion indications and tripling the number of investigational sites in the U.S.
December 10, 2024
,
The one-piece, flexible implant is designed for arthroplasty of the metacarpophalangeal and proximal interphalangeal joints.
December 9, 2024
,
Competitive Landscape
ORTHOWORLD Experts talk you through market forecasts, company sales and key trends.
Industry Voices
